Age-specific ALS Incidence: a Dose-response Meta-analysis
Overview
Authors
Affiliations
To evaluate the association between worldwide ALS incidence rates and age, using a dose-response meta-analysis. We reviewed Medline and Embase up to July 2016 and included all population-based studies of newly-diagnosed cases, using multiple sources for case ascertainment. A dose-response meta-analysis was performed. A meta-regression investigated potential sources of heterogeneity. Of 3254 articles identified in the literature, we included 41 incidence studies covering 42 geographical areas. Overall, the fit between observed and predicted age-specific rates was very good. The expected variation of ALS incidence with age was characterized, in each study, by a progressive increase in the incidence from the 40s leading to a peak in the 60s or 70s, followed by a sharp decrease. Cochran's Q test suggested a significant heterogeneity between studies. Overall, estimated patterns of ALS age-specific incidence (at which the peak was reached) were similar among subcontinents of Europe and North America: peak of ALS incidence ranged in these areas between 6.98 and 8.17/100,000 PYFU, which referred to age in the range 71.6-77.4 years. The relationship between age and ALS incidence appeared different for Eastern Asia which was characterized by a peak of ALS incidence at 2.20/100,000 PYFU around 75 years of age. This study confirms the consistency of the age-specific ALS incidence pattern within different subcontinents. Age-specific incidence appears lower in Eastern Asia as compared to Europe and North America.
Adverse events reporting of edaravone: a real-world analysis from FAERS database.
Shang Q, Zhou J, Ye J, Chen M Sci Rep. 2025; 15(1):8148.
PMID: 40059194 PMC: 11891309. DOI: 10.1038/s41598-025-92605-5.
Statin Use and Amyotrophic Lateral Sclerosis Survival: A Population-Based Cohort Study.
Vaage A, Holmoy T, Dahl J, Stigum H, Meyer H, Nakken O Eur J Neurol. 2025; 32(3):e70095.
PMID: 40034089 PMC: 11876845. DOI: 10.1111/ene.70095.
Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis.
Faller K, Chaytow H, Gillingwater T Nat Rev Neurol. 2025; 21(2):86-102.
PMID: 39743546 DOI: 10.1038/s41582-024-01049-4.
Role of Rho-associated kinases and their inhibitor fasudil in neurodegenerative diseases.
Ye Q, Li X, Gao W, Gao J, Zheng L, Zhang M Front Neurosci. 2024; 18:1481983.
PMID: 39628659 PMC: 11613983. DOI: 10.3389/fnins.2024.1481983.
Clinical features and progress in diagnosis and treatment of amyotrophic lateral sclerosis.
Yuan D, Jiang S, Xu R Ann Med. 2024; 56(1):2399962.
PMID: 39624969 PMC: 11616751. DOI: 10.1080/07853890.2024.2399962.